196 results
Page 6 of 10
8-K
EX-1.1
hqc plf94j
16 Feb 11
Discovery Labs Prices $23.5 Million Public Offering of
12:00am
424B5
czg2 5m0n8v6hf41us1y
15 Feb 11
Prospectus supplement for primary offering
12:00am
8-K
EX-99.1
5285fwf
9 Feb 11
Other Events
12:00am
8-K
yl64ot ws8xpdkbah
9 Feb 11
Other Events
12:00am
8-K
5zq0is2kh5ujwljp3dr3
10 Jan 11
Discovery Labs Provides Update Regarding its Program for Surfaxin® U.S. Marketing Authorization
12:00am
8-K
EX-99.1
yosyiu
10 Jan 11
Discovery Labs Provides Update Regarding its Program for Surfaxin® U.S. Marketing Authorization
12:00am
CORRESP
os4f8p
10 Nov 10
Correspondence with SEC
12:00am
8-K
EX-99.1
1kkg 1u36kq
9 Nov 10
Results of Operations and Financial Condition
12:00am
CORRESP
go8gxl6pqw w0
8 Nov 10
Correspondence with SEC
12:00am
8-K
EX-99.1
jxu5n q0a0bcm
21 Oct 10
Discovery Labs Appoints W. Thomas Amick as Chief Executive Officer
12:00am
CORRESP
tp20l23nwg xwb
1 Oct 10
Correspondence with SEC
12:00am
8-K
EX-1.1
jud4uyuh0ll3
17 Jun 10
Discovery Labs Prices $10.0 Million Public Offering of
12:00am
8-K
EX-99.1
5oz51rla3ku8cs88
9 Jun 10
Discovery Labs Reports Preliminary Results from Phase 2 Clinical Trial of Surfaxin in Pediatric Acute Respiratory Failure
12:00am
8-K
EX-1.1
ocfsl
18 Feb 10
Discovery Labs Prices $16.5 Million Public Offering of
12:00am
8-K
wwz78f98ylc1o7he4za
16 Feb 10
Other Events
12:00am